RNZ
Pharmac is proposing to widen access to a medicine used in the treatment of chronic heart failure.
The medicine, empagliflozin, would be available to people who have chronic heart failure with reduced ejection fraction – about half of all people with chronic heart failure.
Pharmac director of pharmaceuticals Geraldine MacGibbon says empagliflozin is a medicine that can give people more time with their loved ones and lessens the time spent in hospital.